| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;51:773.)
© 2008 American Heart Association, Inc.
Original Articles |
From the Department of Medical Science and Cardio-Renal Medicine (N.A., M.U., Y.Miyagi, M.Y., Y.Miki, K.T., K.U., S.U., T.I.) and the Department of Molecular Pharmacology and Neurobiology (R.A., Y.G.), Yokohama City University Graduate School of Medicine, Kanagawa-ken, Japan.
Correspondence to Tomoaki Ishigami, MD, PhD, Associate Professor, Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama-city, Kanagawa-ken, Japan. E-mail tommmish{at}hotmail.com
| Abstract |
|---|
|
|
|---|
Key Words: tubular transport epithelial sodium channel Nedd4L essential hypertension
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Quantitative Analyses of mRNA for Various Human Tissues
Human kidney, brain, lung, liver, and colon total RNA (BD Biosciences, Bedford, Mass) were prepared for quantitative analysis of Nedd4L mRNA isoforms I and II. Each first-strand cDNA was synthesized from 1 µg total RNA. Quantitative real-time PCR was performed in triplicate using a SYBR RT-PCR Kit (TAKARA), following the manufacturers instructions. Expression of Nedd4L mRNA was normalized to that of GAPDH, used as an endogenous reference.
Electrophysiological Measurement of Amiloride Sensitive Sodium Present by the Voltage Clamp Technique
Human epithelial sodium channel cDNAs (
ENaC:TC119542, βENaC:TC119979, and
ENaC:TC119545) were purchased (Origene Technologies Inc, Rockville, Md). Linearized plasmids were subjected to in vitro transcription using a Message Machine (Ambion) kit to produce capped cRNA for each construct. The integrity of the cRNAs was evaluated by agarose gel electrophoresis. The cRNAs were diluted in water so that 50-nL injections with a Drummond Nanoject oocyte injector carried 1 ng of each cRNA (estimated molar amount of each isoform: isoform I=1.1x10–3 pmol, isoform II=1.1x10–3 pmol, isoform III=1.3x10–3 pmol). Mature female Xenopus laevis were purchased (HSK) and housed in dechlorinated tap water at 18 to 20°C. Stage V and VI oocytes were removed from toads anesthetized in an ice-cold water bath. The oocytes were defolliculated under an inverted stereo microscopic and stored overnight at 18°C in Barths solution (see the data supplement available online at http://hyper.ahajournals.org for further details). After 12 to 24 h, the cRNA was injected into healthy oocytes. Whole cell hENaC currents were measured in voltage-clamp buffer (see the data supplement) 48 h after the cRNA injections, as described previously.9 All recordings were made for at least 5 oocytes at room temperature. Amiloride-sensitive currents were derived by subtracting the currents recorded for 10 µmol/L amiloride from the preamiloride currents.
Immunohistochemistry for Human Kidney Using Rabbit Polyclonal Antibodies Against the Common C2 Domain
A 14-aa synthetic peptide corresponding to amino acids 57 to 70 of the C-terminal tail of human Nedd4L was produced by standard solid-phase peptide synthesis techniques.10 Analysis with BLAST search computer programs showed no significant overlap of the immunizing peptide with any known eukaryotic protein. The peptide was purified, conjugated, and injected 4 times intradermally into rabbits at 2-week intervals to produce polyclonal antiserum. The rabbits had ELISA titers of >1:128 000 before exsanguinations. The selectivity of the antiserum was validated by the recognition of pcDNA3.1-isoform I/ pcDNA3.1isoform II- transfected HEK293T cells by Western blot analysis. Anti-Nedd4L polyclonal antibodies were affinity-purified and used in the present study. Immunohistochemical analysis of the human kidney sections was performed with biotinylated goat antirabbit IgG diaminobenzidine (DAB) was used for visualization of the labeled antibodies. The sections were counterstained with hematoxylin, dehydrated, and mounted. Human kidney tissues were obtained from kidney specimens of patient with renal cell carcinoma. Written informed consent was obtained from the subject. This study was approved by the Medical Ethical Committee of Yokohama City University School of Medicine in 2004.
Cellular Localization of Human Nedd4L Isoform I by Fluorescent Confocal Microscopy During Calcium Stimulation
mIMCD-3 cells were seeded on 24-well plates the day before gene transfection. The His-tagged Neddd4L isoform I in pcDNA3.1 was transiently transfected in mIMCD-3 cells, using FuGENE6 (Roche Applied Science). Forty-eight hours after transfection, the cells were divided into 2 groups and exposed to different conditions. One group of cells was treated with CaCl2 (1 mmol/L) plus ionomycin (1 mmol/L) for 10 min, and the other was untreated to serve as a control. Subsequently, the cells were fixed and permeabilized with 2% paraformaldehyde and 0.1% Triton X-100. Nedd4L isoform I was detected with mouse anti-His antibody and Alexa Fluora 488-labeled antimouse IgG (green label) (Invitrogen-Molecular Probe) as the secondary antibody. The cellular localization of the isoform was observed with a confocal microscope (model LSM510, Carl Zeiss).
Statistical Analysis
Values are expressed as means±SE in both the text and figures. The data were analyzed by analysis of variance. If a statistically significant effect was found, a post hoc analysis (Tukey HSD post hoc test) was performed to detect differences between the groups. Values of P<0.05 were considered to indicate statistical significance.
| Results |
|---|
|
|
|---|
|
Isoform I Is Expressed Predominantly in the Kidney and Isoform II Predominantly in the Lung
Figure 2 shows the results of quantitative analyses of the expression of the mRNA of human Nedd4L isoforms I and II in the kidney, lung, brain, liver, and colon. Human isoform I was significantly more abundantly expressed in the kidney (P<0.001), whereas human isoform II was significantly more abundantly expressed in the lung (P<0.001).
|
Dominant Negative Interactions of Human Nedd4L Isoform I Protein With the Two Other Isoforms
To study the effect of the 3 human Nedd4L isoforms on Na transport, we expressed ENaC with or without each Nedd4L isoform in xenopus oocytes followed by whole cell voltage clamp and amiloride-sensitive current measurements. We found that Nedd4L isoform II and isoform III both robustly reduced the ENaC present (bar graphs 3 and 5). In contrast, Nedd4L isoform I did not reduce the ENaC present (bar graph 2), but suppressed Nedd4L isoform II and III activities for downregulating ENaC, because the ENaC current for both isoforms II and III was restored by coinjection of isoform I (bar graphs 4 and 6). These results show that both human Nedd4L isoforms II and III can interact with and downregulate ENaC activities in a reconstituted system, whereas human Nedd4L isoform I has significant antagonistic activity against the 2 other isoforms (Figure 3).
|
Human Nedd4L Protein With C2 Domain Is Expressed Along the Aldosterone-Sensitive Distal Nephron
Panels A to D of Figure 4 show representative findings of the immunohistochemical analyses of the human kidney, using polyclonal antibodies against the common C2 domain. Positive staining was observed in the connecting tubules and cortical collecting ducts, identified as clusters of tubular sections near radial veins in the cortical labyrinths both the inner-medullary and outer-medullary collecting ducts were simultaneously stained. We also performed nonimmune IgG staining of the human kidney but obtained no specific staining with this method (data not shown).
|
Human Nedd4L Isoform I Was Targeted to the Cell Surface Membrane by Calcium Overload
Figure 5 shows representative findings for human Nedd4L isoform I on confocal fluorescence microscopy after calcium overload. Cytosomal expression of human Nedd4L isoform I without any stimulation is shown in panel A. After calcium overload stimulation, cellular membrane staining was enhanced (panel B), suggesting membrane targeted binding of the protein.
|
| Discussion |
|---|
|
|
|---|
The possibility that Na reabsorption in the distal tubule contributes to high blood pressure was first suggested by an analysis of inherited high blood pressure by Lifton et al.11–14 It is generally accepted that blood pressure rises because of increased peripheral vascular resistance attributable to an excess of body fluid, which takes place against the background of accelerated sodium reabsorption by the ion transporter for which is distributed in the distal tubule. Such a model may represent the mechanism underlying sodium sensitivity in essential hypertension.
As for the ENaC-related type, which exhibits amiloride sensitivity, the mechanism for developing high blood pressure is clear from the excessive appearance of ENaC on the apical side of the urinary tubule, as is especially evident in Liddle syndrome.15–17 Ubiquitination of the Lys residues on the N terminus of ENaC, mediated by the WW domain of Nedd4L binding to the PY motif in the C terminus, has an important role in the accumulation and retrieval of ENaC from the cell surface,15–17 and a gene mutation has been discovered in the PY motif in Liddle syndrome.13,14,18 Ubiquitination was abolished by the presence of a gene mutation in the PY motif, and ENaCs continuously appeared on the apical side of the urinary tubule. The dominance of Nedd4L as a ubiquitination enzyme was initially based on the discovery of interactions between the PY motif and Nedd4.15 Nedd4L is now considered the main ubiquitination enzyme for ENaC.19–22
Dunn and Ishigami et al previously demonstrated the existence of the C2 domain of human Nedd4L by applying resequencing and bioinfomatic methods to the genomic DNA of the human Nedd4L gene.4 There is a peculiar isoform of Nedd4L in humans, resulting from a single-nucleotide polymorphism (SNP) at the end of exon 1. A significant relation between this SNP and blood pressure was recently demonstrated by 24-hour ambulatory blood pressure monitoring,5 and we have since independently shown a similar relation in a Japanese man.8 Available evidence thus suggests that one of the isoforms of the human Nedd4L gene is related to the development of essential hypertension. This relation is supported by findings obtained by our laboratory10 and others,23 showing that the Nedd4L gene and Nedd4L protein are involved in the appearance of high blood pressure with sodium sensitivity in a rodent model of hypertension. Therefore, our study analyzed the expression, appearance, and protein interactions of the human Nedd4L gene isoform I in detail. Quantitative PCR showed that isoform I was abundantly expressed in the kidney, whereas isoform II was mainly expressed in the lung. Because ENaC is expressed in lung, kidney, and colon epithelial cells, the control of ENaC in these organs might be differentially regulated by different isoforms. The ENaC current was also measured using a heterologous gene expression system in xenopus oocytes, and interactions among the different isoforms of Nedd4L were examined. Immunohistochemical analysis of kidney sections showed that human Nedd4L protein was expressed in the ASDN, where ENaC is thought to be the major ion-transporter for sodium reabsorption. This finding suggested that ENaC and Nedd4L protein might be to be colocalized functionally as well as anatomically. We performed immunohistochemical analysis in humans for the first time, although we had previously studied the organization of the Nedd4L gene/protein by means of in situ hybridization/immunohistochemistry analyses in rodents and by in situ hybridization in the human kidney.10 The protein was found only in the ASDN with fair staining, similar to our previous observations for transcripts of the Nedd4L gene in humans.
Phylogenic analysis has demonstrated that the Nedd4L isoform II has the ancestral C2 domain.4 This conserved C2 domain can reportedly mobilize to the cell surface membrane, increasing the density of calcium in the cell.24,25 In this study, mobilization of human Nedd4L isoform I to the cell surface was confirmed to take place in a calcium-dependent manner, although the N-terminal amino acid sequence differs between isoforms I and II. Whether this conserved cellular membrane-targeting property influenced the withdrawal of ENaC from the cell surface remains unclear. This issue needs to be addressed in a different manner to clarify the effects of calcium in vitro as well as in vivo.
The possibility that retrieval or downregulation of ENaC by isoform II/III protein is controlled by Nedd4L isoform I was suggested by the results of experiments in xenopus oocytes. However, our experiments were limited, and our results in this experimental system cannot be directly extrapolated to humans.
Taken together, our findings provide possible evidence that the human Nedd4L gene is a candidate gene for hypertension. Isoform I protein appears to be an evolutionarily new peptide caused by a uniquely human SNP, variant 13(G/A) (rs4149601). These proteins have a potential property to move to cellular membrane by calcium stimulation as isoform II have, and is expressed in the ASDN of kidneys. The expression of ENaC might be relatively increased by interactions with isoforms II, isoform III, or both, appearing in the same cells in association with the high blood pressure syndrome.
Perspectives
Future detailed analyses of the pathophysiological relevance of the Nedd4L gene in essential hypertension are expected to shed light on the mechanism underlying the activation of human Nedd4L isoform I, leading to the development of medicinal tools capable of modifying the ENaC-Nedd4L-proteasome axis in tubular epithelium. Therapeutic interventions targeting the ENaC-Nedd4L-proteasome system in the high blood pressure syndrome are based on the premise that a functional abnormality is present at the molecular level. Such new treatments might hopefully improve the outcomes of patients with cardiovascular events associated with essential hypertension.
| Acknowledgments |
|---|
This work is supported by Grant-in-Aid for Scientific Research of The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) No. 0018590898 (to T.I.).
Disclosures
None.
Received October 1, 2007; first decision October 24, 2007; accepted January 8, 2008.
| References |
|---|
|
|
|---|
2. Thomas CP, Itani OA. New insights into epithelial sodium channel function in the kidney: site of action, regulation by ubiquitin ligases, serum- and glucocorticoid-inducible kinase and proteolysis. Curr Opin Nephrol Hypertens. 2004; 13: 541–548.[Medline] [Order article via Infotrieve]
3. Staub O, Rotin D. Role of ubiquitylation in cellular membrane transport. Physiol Rev. 2006; 86: 669–707.
4. Dunn DM, Ishigami T, Pankow J, von Niederhausern A, Alder J, Hunt SC, Leppert MF, Lalouel JM, Weiss RB. Common variant of human NEDD4L activates a cryptic splice site to form a frameshifted transcript. J Hum Genet. 2002; 47: 665–676.[CrossRef][Medline] [Order article via Infotrieve]
5. Fava C, von Wowern F, Berglund G, Carlson J, Hedblad B, Rosberg L, Burri P, Almgren P, Melander O. 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes. Kidney Int. 2006; 70: 562–569.[Medline] [Order article via Infotrieve]
6. Sile S, Velez DR, Gillani NB, Alexander CR, George AL Jr, Williams SM. Haplotype diversity in four genes (CLCNKA, CLCNKB, BSND, NEDD4L) involved in renal salt reabsorption. Hum Hered. 2008; 65: 33–46.[CrossRef][Medline] [Order article via Infotrieve]
7. Dahlberg J, Nilsson LO, von Wowern F, Melander O. Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. PLoS ONE. 2007; 2: e432.[CrossRef]
8. Ishigami T, Umemura M, Araki N, Hirawa N, Tamura K, Uchino K, Umemura S, Rohrwasser A, Lalouel JM. NEDD4L protein truncating variant (v13(G/A):rs4149601) is associated with essential hypertension (EH) in a sample of the Japanese population. Geriatrics Geront Int. 2007; 7: 114–118.[CrossRef]
9. Nakamura F, Goshima Y, Strittmatter SM, Kawamoto S. Isolation of receptor clones by expression screening in Xenopus oocytes. Methods Mol Biol. 1999; 128: 1–18.[Medline] [Order article via Infotrieve]
10. Umemura M, Ishigami T, Tamura K, Sakai M, Miyagi Y, Nagahama K, Aoki I, Uchino K, Rohrwasser A, Lalouel JM, Umemura S. Transcriptional diversity and expression of NEDD4L gene in distal nephron. Biochem Biophys Res Commun. 2006; 339: 1129–1137.[Medline] [Order article via Infotrieve]
11. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001; 104: 545–556.[CrossRef][Medline] [Order article via Infotrieve]
12. Lifton RP. Genetic determinants of human hypertension. Proc Natl Acad Sci U S A. 1995; 92: 8545–8551.
13. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995; 11: 76–82.[CrossRef][Medline] [Order article via Infotrieve]
14. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW. Liddles syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994; 79: 407–414.[CrossRef][Medline] [Order article via Infotrieve]
15. Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D. WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddles syndrome. EMBO J. 1996; 15: 2371–2380.[Medline] [Order article via Infotrieve]
16. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, Schild L, Rotin D. Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J. 1997; 16: 6325–6336.[CrossRef][Medline] [Order article via Infotrieve]
17. Plant PJ, Yeger H, Staub O, Howard P, Rotin D. The C2 domain of the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma membrane localization. J Biol Chem. 1997; 272: 32329–32336.
18. Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, Nelson-Williams C, Rossier BC, Lifton RP. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A. 1995; 92: 11495–11499.
19. Kamynina E, Staub O. Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na(+) transport. Am J Physiol Renal Physiol. 2002; 283: F377–F387.
20. Kamynina E, Tauxe C, Staub O. Distinct characteristics of two human Nedd4 proteins with respect to epithelial Na(+) channel regulation. Am J Physiol Renal Physiol. 2001; 281: F469–F477.
21. Harvey KF, Dinudom A, Cook DI, Kumar S. The Nedd4-like protein KIAA0439 is a potential regulator of the epithelial sodium channel. J Biol Chem. 2001; 276: 8597–8601.
22. Flores SY, Debonneville C, Staub O. The role of Nedd4/Nedd4-like dependant ubiquitylation in epithelial transport processes. Pflugers Arch. 2003; 446: 334–338.[Medline] [Order article via Infotrieve]
23. Loffing-Cueni D, Flores SY, Sauter D, Daidie D, Siegrist N, Meneton P, Staub O, Loffing J. Dietary sodium intake regulates the ubiquitin-protein ligase Nedd4-2 in the renal collecting system. J Am Soc Nephrol. 2006; 17: 1264–1274.
24. Itani OA, Stokes JB, Thomas CP. Nedd4-2 isoforms differentially associate with ENaC and regulate its activity. Am J Physiol Renal Physiol. 2005; 289: F334–F346.
25. Plant PJ, Lafont F, Lecat S, Verkade P, Simons K, Rotin D. Apical membrane targeting of Nedd4 is mediated by an association of its C2 domain with annexin XIIIb. J Cell Biol. 2000; 149: 1473–1484.
This article has been cited by other articles:
![]() |
F. Luo, Y. Wang, X. Wang, K. Sun, X. Zhou, and R. Hui A Functional Variant of NEDD4L Is Associated With Hypertension, Antihypertensive Response, and Orthostatic Hypotension Hypertension, October 1, 2009; 54(4): 796 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Rossier and L. Schild Epithelial Sodium Channel: Mendelian Versus Essential Hypertension Hypertension, October 1, 2008; 52(4): 595 - 600. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |